Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 122

1.

CNS atypical T-cell lymphoproliferative disease following treatment with alemtuzumab.

Khan M, Ney DE, Kleinschmidt-DeMasters BK, Horton L, Alvarez E, Piquet AL.

Neurol Clin Pract. 2019 Jun;9(3):273-276. doi: 10.1212/CPJ.0000000000000639. No abstract available.

PMID:
31341717
2.

B cell depletion with ublituximab reshapes the T cell profile in multiple sclerosis patients.

Lovett-Racke AE, Gormley M, Liu Y, Yang Y, Graham C, Wray S, Racke MK, Shubin R, Twyman C, Alvarez E, Bass A, Eubanks JL, Fox E.

J Neuroimmunol. 2019 Jul 15;332:187-197. doi: 10.1016/j.jneuroim.2019.04.017. Epub 2019 May 3.

3.

Monoclonal Antibodies in Multiple Sclerosis: Present and Future.

Voge NV, Alvarez E.

Biomedicines. 2019 Mar 14;7(1). pii: E20. doi: 10.3390/biomedicines7010020. Review.

4.

Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment.

Vollmer BL, Nair KV, Sillau S, Corboy JR, Vollmer T, Alvarez E.

Ann Clin Transl Neurol. 2018 Dec 9;6(2):252-262. doi: 10.1002/acn3.700. eCollection 2019 Feb.

5.

Subjective cognitive concern in multiple sclerosis is associated with reduced thalamic and cortical gray matter volumes.

Kletenik I, Alvarez E, Honce JM, Valdez B, Vollmer TL, Medina LD.

Mult Scler J Exp Transl Clin. 2019 Feb 13;5(1):2055217319827618. doi: 10.1177/2055217319827618. eCollection 2019 Jan-Mar.

6.

Real-World Characterization of Dimethyl Fumarate-Related Gastrointestinal Events in Multiple Sclerosis: Management Strategies to Improve Persistence on Treatment and Patient Outcomes.

Min J, Cohan S, Alvarez E, Sloane J, Phillips JT, van der Walt A, Koulinska I, Fang F, Miller C, Chan A.

Neurol Ther. 2019 Jun;8(1):109-119. doi: 10.1007/s40120-019-0127-2. Epub 2019 Jan 31.

7.

Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis.

Honce JM, Nair KV, Sillau S, Valdez B, Miravalle A, Alvarez E, Schreiner T, Corboy JR, Vollmer TL.

Neurology. 2019 Feb 12;92(7):e723-e732. doi: 10.1212/WNL.0000000000006916. Epub 2019 Jan 11.

PMID:
30635477
8.

Evaluation of a Novel Preference Assessment Tool for Patients with Multiple Sclerosis.

Col NF, Solomon AJ, Springmann V, Ionete C, Alvarez E, Tierman B, Kutz C, Morales IB, Griffin C, Ngo LH, Jones DE, Phillips G, Hopson A, Pbert L.

Int J MS Care. 2018 Nov-Dec;20(6):260-267. doi: 10.7224/1537-2073.2017-021.

9.

Exploring cannabis use by patients with multiple sclerosis in a state where cannabis is legal.

Weinkle L, Domen CH, Shelton I, Sillau S, Nair K, Alvarez E.

Mult Scler Relat Disord. 2019 Jan;27:383-390. doi: 10.1016/j.msard.2018.11.022. Epub 2018 Nov 20.

PMID:
30502644
10.

We need to conduct clinical trials of disease-modifying therapy in pregnancy to optimize care of women with MS - Yes.

Alvarez E, Mowry EM.

Mult Scler. 2019 Feb;25(2):187-188. doi: 10.1177/1352458518794061. Epub 2018 Oct 22. No abstract available.

PMID:
30346221
11.

Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: A retrospective analysis of the multiple sclerosis, clinical and MRI outcomes in the USA (MS-MRIUS) study.

Zivadinov R, Medin J, Khan N, Korn JR, Chitnis T, Naismith RT, Alvarez E, Dwyer MG, Bergsland N, Carl E, Silva D, Weinstock-Guttman B; MS-MRIUS Study Group.

Mult Scler Relat Disord. 2019 Jan;27:65-73. doi: 10.1016/j.msard.2018.09.037. Epub 2018 Oct 3.

PMID:
30342416
12.

Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.

Fox RJ, Coffey CS, Conwit R, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Naismith RT, Ashokkumar A, Barnes J, Ecklund D, Klingner E, Koepp M, Long JD, Natarajan S, Thornell B, Yankey J, Bermel RA, Debbins JP, Huang X, Jagodnik P, Lowe MJ, Nakamura K, Narayanan S, Sakaie KE, Thoomukuntla B, Zhou X, Krieger S, Alvarez E, Apperson M, Bashir K, Cohen BA, Coyle PK, Delgado S, Dewitt LD, Flores A, Giesser BS, Goldman MD, Jubelt B, Lava N, Lynch SG, Moses H, Ontaneda D, Perumal JS, Racke M, Repovic P, Riley CS, Severson C, Shinnar S, Suski V, Weinstock-Guttman B, Yadav V, Zabeti A; NN102/SPRINT-MS Trial Investigators.

N Engl J Med. 2018 Aug 30;379(9):846-855. doi: 10.1056/NEJMoa1803583.

13.

Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers.

Vollmer B, Ontaneda D, Bandyopadhyay A, Cohn S, Nair K, Sillau S, Bermel RA, Corboy JR, Fox RJ, Vollmer T, Cohen JA, Alvarez E, Hersh CM.

Neurol Clin Pract. 2018 Aug;8(4):292-301. doi: 10.1212/CPJ.0000000000000487.

14.

The impact of very short transition times on switching from Natalizumab to Fingolimod on imaging and clinical effectiveness outcomes in multiple sclerosis.

Vollmer B, Honce JM, Sillau S, Corboy JR, Vollmer T, Nair K, Alvarez E.

J Neurol Sci. 2018 Jul 15;390:89-93. doi: 10.1016/j.jns.2018.04.021. Epub 2018 Apr 13.

PMID:
29801915
15.

Fingolimod's Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MS-MRIUS.

Zivadinov R, Medin J, Khan N, Korn JR, Bergsland N, Dwyer MG, Chitnis T, Naismith RT, Alvarez E, Kinkel P, Cohan S, Hunter SF, Silva D, Weinstock-Guttman B; MS-MRIUS investigators.

J Neuroimaging. 2018 Jul;28(4):399-405. doi: 10.1111/jon.12518. Epub 2018 May 11.

PMID:
29749661
16.

Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification.

Echavarria I, López-Tarruella S, Picornell A, García-Saenz JÁ, Jerez Y, Hoadley K, Gómez HL, Moreno F, Monte-Millan MD, Márquez-Rodas I, Alvarez E, Ramos-Medina R, Gayarre J, Massarrah T, Ocaña I, Cebollero M, Fuentes H, Barnadas A, Ballesteros AI, Bohn U, Perou CM, Martin M.

Clin Cancer Res. 2018 Apr 15;24(8):1845-1852. doi: 10.1158/1078-0432.CCR-17-1912. Epub 2018 Jan 29.

17.

Pulse Width Does Not Influence the Gains Achieved With Neuromuscular Electrical Stimulation in People With Multiple Sclerosis: Double-Blind, Randomized Trial.

Almuklass AM, Davis L, Hamilton LD, Hebert JR, Alvarez E, Enoka RM.

Neurorehabil Neural Repair. 2018 Jan;32(1):84-93. doi: 10.1177/1545968317753681. Epub 2018 Jan 24.

18.

High risk of postpartum relapses in neuromyelitis optica spectrum disorder.

Klawiter EC, Bove R, Elsone L, Alvarez E, Borisow N, Cortez M, Mateen F, Mealy MA, Sorum J, Mutch K, Tobyne SM, Ruprecht K, Buckle G, Levy M, Wingerchuk D, Paul F, Cross AH, Jacobs A, Chitnis T, Weinshenker B.

Neurology. 2017 Nov 28;89(22):2238-2244. doi: 10.1212/WNL.0000000000004681. Epub 2017 Nov 1.

19.

PD-L1 Overexpression During Endotoxin Tolerance Impairs the Adaptive Immune Response in Septic Patients via HIF1α.

Avendaño-Ortiz J, Maroun-Eid C, Martín-Quirós A, Toledano V, Cubillos-Zapata C, Gómez-Campelo P, Varela-Serrano A, Casas-Martin J, Llanos-González E, Alvarez E, García-Río F, Aguirre LA, Hernández-Jiménez E, López-Collazo E.

J Infect Dis. 2018 Jan 17;217(3):393-404. doi: 10.1093/infdis/jix279.

PMID:
28973671
20.

Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: Two-year experience.

Vollmer B, Nair KV, Sillau SH, Corboy J, Vollmer T, Alvarez E.

Mult Scler J Exp Transl Clin. 2017 Aug 17;3(3):2055217317725102. doi: 10.1177/2055217317725102. eCollection 2017 Jul-Sep.

Supplemental Content

Loading ...
Support Center